Peginterferon alfa-2a is a modified form of recombinant human interferon used to stimulate the innate antiviral response in the treatment of hepatitis B and C viruses. Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
- Mechanism
- Curator reviewed
Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response.
- Primary indication
- Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease.Curator reviewed · 5 structured indications
- Formula / weight
- 60000.0 Da
- First approval
- Canada, 2003 · United States, 2002 · European Union, 2016
- Also known as
- Pegylated Interfeaon alfa-2A · Pegylated interferon alfa-2a · Pegylated Interferon alpha 2a · Pegylated interferon alpha-2a · Pegylated-interferon alfa 2a
- Code names
- RO 25-8310/000
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Peginterferon alfa-2a, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account